Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: USA TODAY
It worked. Ohio Attorney General Dave Yost dropped out after losing the Ohio Republican Party's endorsement to Ramaswamy . Lt. Gov. Jim Tressel, a prominent former head football coach at Ohio State University, decided not to run. Ramaswamy , a 40-year-old biotech billionaire backed by a who's who of GOP politics , heads into the May 5 Republican primary as the front-runner - but not the only name on the ballot. He'll face Casey Putsch , a northwest Ohio business owner, car enthusiast and watchmaker, and Heather Hill , a former school board president from southeast Ohio. The Republican primary is less about whether Ramaswamy will win and more about how much Ramaswamy can inspire Ohio's GOP base to hit the polls. The winner will face former Ohio Department of Health director Dr. Amy Acton, who has no Democratic primary opponent, and Libertarian Donald Kissick. Some Republicans have criticized Ramaswamy for defending businesses' use of foreign-born workers . Ramaswamy initially sa
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]Seeking Alpha
- Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript [Seeking Alpha]Seeking Alpha
- Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint [Yahoo! Finance]Yahoo! Finance
- Immunovant falls on late-stage trial setback for TED therapy [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/10/26 - Form 4
- 4/8/26 - Form 144
- 4/2/26 - Form 4
- ROIV's page on the SEC website